Trial reportThe Journal of asthma : official journal of the Association for the Care of Asthma2014
Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses.
Trial report in The Journal of asthma : official journal of the Association for the Care of Asthma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 12 Week Randomized, Double-blind, Double-Dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Children (at Least 6years of Age) and Adults With Asthma-SPRUCE 80/4.5
A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Distinct phenotype and risk factor analysis of persistent airflow limitation among asthmatic children: a case-control study.BMC pediatrics · 2024Article
- Phenotyping asthma with airflow obstruction in middle-aged and older adults: a CADSET clinical research collaboration.BMJ open respiratory research · 2023Article
- Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.Advances in therapy · 2022Article
- Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER.Clinical and translational allergy · 2022Article
- Asthma with Fixed Airflow Obstruction: From Fixed to Personalized Approach.Journal of personalized medicine · 2022Review
- Sex and gender in asthma.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Effects of Air Pollutant Exposure on Exacerbation Severity in Asthma Patients with or without Reversible Airflow Obstruction.Journal of asthma and allergy · 2021Article
- Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats.Chinese medical journal · 2019Article
- Review
- Gut microbiota components are associated with fixed airway obstruction in asthmatic patients living in the tropics.Scientific reports · 2018Article
- Targeted Therapy for Severe Asthma: Identifying the Right Patients.Molecular diagnosis & therapy · 2017Review
- The asthma-COPD overlap syndrome: how is it defined and what are its clinical implications?Journal of asthma and allergy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of fixed airflow obstruction (FAO) in asthma is unclear.
objectiveTo assess the relationship between FAO and clinical features of asthma and the effect of FAO on treatment response.
methodsPost hoc descriptive analysis of data stratified by FAO category (screening post-albuterol FEV1/FVC <lower limit of normal [LLN] [FAO+] or ≥LLN [FAO-]) from two 12-week, randomized, placebo-controlled studies of budesonide/formoterol or the monocomponents in mild-moderate (study I; aged ≥6 years; NCT00651651; placebo run-in) or moderate-severe (study II; ≥12 years; NCT00652002; budesonide run-in) asthma patients.
resultsAt baseline, FAO+ versus FAO- patients were more likely male and had longer asthma duration and worse pulmonary function. During the treatment period, lung function and asthma control measures with placebo were generally worse in FAO+ versus FAO- patients. Budesonide was effective on most end points in both FAO+ and FAO- patients. In contrast to FAO- patients, FAO+ patients were unresponsive to formoterol monotherapy in both study populations. Consistently greater improvements in most end points (including worsening of asthma as predefined by specific lung function parameters or clinical symptoms) were observed moving from formoterol to budesonide to budesonide/formoterol in both FAO+ and FAO- patients, with generally greater than additive effects on lung function with budesonide/formoterol in FAO+ patients.
conclusionsFAO+ patients tended to be more impaired and at greater risk for an asthma event versus FAO- patients. While FAO+ patients were non-responsive to formoterol monotherapy, they retained responsiveness to budesonide and had the greatest lung function and control responses to budesonide/formoterol that were similar to or greater than responses of FAO- patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.